Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors
Risks
Default risk
Data is available to registered users only
Volatility
Data is available to registered users only
Selling difficulty
Data is available to registered users only
Stress test
Data is available to registered users only
Country risks
Data is available to registered users only
Other risks
Data is available to registered users only
Sign up to access detailed risk analysis
About
Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market. Its extensive intellectual property portfolio addresses a variety of medical conditions, with programs currently in pre-clinical animal stages. These include initiatives for Parkinson's disease, neuropathic and chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. Formed in 2001 and headquartered in Las Vegas, Nevada, the company was formerly known as Growblox Sciences, Inc. before rebranding in October 2016.